Significant shareholders:
| Shareholder/Beneficial Owner | Shares | % ISC |
|---|---|---|
| Invesco | 142,305,599 | 17.68 |
| Lombard Odier Investment Managers | 81,452,878 | 10.12 |
| T Rowe Price Global Investments | 79,122,144 | 9.83 |
| Canaccord Genuity Wealth Management | 71,716,260 | 8.91 |
| Hargreaves Lansdown, stockbrokers | 50,306,277 | 6.25 |
| Dr Andrew Nelson* | 40,567,234 | 5.04 |
| Interactive Investor | 39,846,273 | 4.95 |
as at 31 January 2023
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 804,885,350 Ordinary shares.
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 33.8%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: The Company holds 4,115 Ordinary Shares in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings.